Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
Jamal Rana, Assistant Physician in Chief at The Permanente Medical Group, in Pleasanton, California, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Our another exciting paper, led by Iribarren, published in American Journal of Preventive Cardiology. Interplay between family history and polygenic risk for coronary heart disease (CHD).
Family history of heart disease is a recognized risk factor. However, it is considered to have low accuracy due to recall bias. Likely reason it is not part of the risk factor base risk calculators such as PREVENT.
Cohort comprised of 61,352 individuals from Kaiser Permanente with follow-up time of 14 years.
Individuals underwent polygenic risk scoring PRS (CARDIO inCode-Score CHD PRS, GENinCode Plc).
PRS and family history CHD were positively correlated, and both independently contribute to risk of incident CHD.
High PRS was associated with similar increased CHD risk in persons with and without family history CHD. A key finding of this study is therefore the fact that PRS adds to risk information among individuals with negative family history.
Hazard ratio, due to joint effect of positive family history CHD and high PRS was well above two.
These results have important clinical implications because relying solely on self-reported family history is insufficient to fully characterize the genetic contribution to CHD and thus the use of PRS could complement traditional risk algorithms particularly among subjects with no known family history of CHD.”
Title: Interplay between family history and polygenic risk for coronary heart disease: A cohort study among over 60 thousand individuals
Authors: Carlos Iribarren, Meng Lu, Roberto Elosua, Martha Gulati, Nathan D. Wong, Jamal S.Rana
Read the Full Article on American Journal of Preventive Cardiology.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery